CEFPODOXIME 50MG WITH CLAVULANIC ACID 31.25MG DRY SYRUP is a formulation Dry-powder form contains active ingredients Cefpodoxime Clavulanic Acid. CEFPODOXIME 50MG WITH CLAVULANIC ACID 31.25MG DRY SYRUP is a dry form of a syrup formulation designed as a dry form that is reconstituted by the addition of water to a defined specification of a product label instructions. The dosage form CEFPODOXIME 50MG WITH CLAVULANIC ACID 31.25MG DRY SYRUP in a PCD Pharma Portfolio requires to refer the powder characteristics, stability, and compatibility of ingredients, reconstitution.
The finished product formulation comprises the active pharmaceutical ingredients and appropriate excipients, chosen based on the physical and chemical properties aimed to be achieved in the final preparation. The excipients may be suspending agents, sweetening agents, flavoring agents, buffering agents, stabilisers, diluents, and so on as per the final manufacturing formula.
The dry syrup, on the other hand is produced and can be packed in powder form, not as a ready-to-use liquid preparation. Powder products can be produced and filled under controlled moisture conditions. After filling, the powder product needs to flow and be stable until reconstituted.
After being well dispersed with the excipients and prepared as a powder mixture, a dry formulation of Cefpodoxime and Clavulanic Acid is produced. During the formulation process, physical characteristics of the powder mixture are monitored to ensure proper flowability of the final product. The powder mixture's physical properties include particle size, density, flowability, and moisture content.
Materials are usually identified and quality tested before they are approved to manufacture the pharmaceutical product. Depending on the formulation design, materials may be sieved, milled, or otherwise controlled for particle size. The aim is to produce a powder system that can provide sufficient blend uniformity.
Low-concentration ingredients and functional excipients should be added and blended under controlled conditions. Premix might be used if suitable, to aid uniformity of distribution within the batch. Mixing time, order of addition, loading conditions of the equipment and other environmental factors may affect the final blend.
For dry syrup production, moisture control is an important issue. Too high a humidity during processing can influence powder flow, agglomeration, and stability during storage. Areas of production and handling of materials can be constructed to optimize humidity during processing.
CEFPODOXIME 50MG WITH CLAVULANIC ACID 31.25MG DRY SYRUP PROCESS The manufacturing process of CEFPODOXIME 50MG WITH CLAVULANIC ACID 31.25MG DRY SYRUP Usually starts with dispensing of quality raw materials as per the master manufacturing formula. The ingredients are weighed on calibrated weighing scales and verification is done for each quantity.
Subsequently, the ingredients can be sieved using appropriate sieves to remove any unwanted agglomerates and ensure the desired particle properties are obtained. The active ingredients and excipients are then mixed in a pre-specified order. For some product types it may be advantageous to implement a set of dry-blending or granulation process steps.
Following blending the bulk powder will undergo the appropriate in-process quality checks. These may include, but are not limited to, blend uniformity, moisture content, bulk density, flow characteristics and visual appearance based on predefined specifications.
The dry powder is then transferred by fillers to the relevant pharmaceutical grade bottles. The dosage bottles are filled using specific equipment by weight; the fill weight is controlled during this process to ensure uniformity of weight of the product per bottle. The finished product is capped using the relevant closure to prevent exposure to air.
Among the most critical development considerations for a dry syrup (DS) is its physical stability following reconstitution. The powder formulation should be such that the addition of the specified amount of water yields a homogenous liquid preparation with appropriate physical properties.
A: As part of the formulation design, formulation scientists would consider measures such as the wetting ability, dispersibility, sedimentation, dispersibility, viscosity, pH, appearance, and the overall suspension uniformity, depending on the design of the formulation. Suspending agents may be added to help preserve an adequate dispersion of insoluble particles during reconstitution.
Particle size distribution The powder's particle size distribution can also have an impact on the resulting suspension. Extremely large particles can influence proper dispersion of the product; extremely fine particles can have an effect on flow, wetting or agglomeration. Hence particle engineering and excipients choice are part of the formulation development.
Different lot reconstitution studies can be carried out to check for consistency. The reconstituted sample may be analyzed for physical description and homogeneity throughout the specified period. These studies are helpful to determine appropriate manufacturing parameters as well as packing specifications.
PRODUCT QUALITY CONTROL FOR CEFPODOXIME 50MG WITH CLAVULANIC ACID 31.25MG DRY SYRUP The quality control tests should be performed on the dry powder in the initial step and then on the reconstituted preparation in accordance with the relevant specifications. This may be achieved by such tests as: identification and assay of the active substances, related compounds, moisture, powder properties, micro-organisms content etc.
The performance of all the analytical methods for Cefpodoxime and Clavulanic Acid should be validated as required to produce satisfactory results. Representative sampling of the product should be performed as it is a multi-ingredient powder and representative samples allow batch uniformity to be assessed.
Packaging It also plays an important role. Depending on the stability characteristics of the formulation, the right closure and a pharmaceutical grade bottle may be chosen. During development of the packaging, factors such as moisture-barrier characteristics, container compatibility and protection and sealing integrity during transportation may be taken into account.
The label must also include the normal product information, batch details, manufacturing details, expiry details, and any other regulatory details. The packaging design can be used to identify the product, and to professionalize the appearance of your portfolio of pharmaceutical products.
Standard therapies- A dry syrup Cefpodoxime 50MG with Clavulanic Acid 31.25MG (Dry Syrup) can be added to a larger set of pharma products as other strengths and other formulations. Standardizing manufacturing of a medicinal product enables pharma companies to control quality, documentation, packaging, and supply-chain requirements more effectively.
In the typical product development of the finished drug product, there is a close coordinated activity between formulation development, production, quality assurance, quality control, regulatory personnel and packaging personnel. All this serves to keep the product at its desired specifications in the FDM.
Special considerations for pharma manufacturers offering multiple products For pharma manufacturers offering many SKUs, dry syrups are an easy and efficient pathway to establishing a high-quality product portfolio. Special focus should be given to moisture management, powder flow, reconstitution attributes, container-closure systems, and stability.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech